Puma Biotechnology Inc — Quarterly Cash Flow (NASDAQ:PBYI) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Total assets 220.72 M213.33 M196.18 M194.92 M202.86 M216.3 M Total liabilities 149.63 M121.21 M99.07 M90.2 M87.59 M85.96 M Total equity 71.09 M92.13 M97.11 M104.72 M115.27 M130.34 M Total liabilities & shareholders' equities 220.72 M213.33 M196.18 M194.92 M202.86 M216.3 M Total debt —————— Net debt ——————

Puma Biotechnology Inc

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Новости

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-02-27

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates

Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates

Is VTI a Good ETF? A Quick Snapshot for Investors —1/21/25 - TipRanks.com

Douglas Hunt, vicepresidente senior de Puma Biotechnology, vende acciones PBYI por 52.695 dólares

Douglas Hunt, VP de Puma Biotechnology, vende acciones por $52,695 en PBYI

CFO de Puma Biotech Nougues vende acciones por $64,000

CFO de Puma Biotech Nougues vende acciones por 64.000 dólares

Hunt Douglas, SVP at Puma Biotechnology, sells $52,695 in PBYI

Puma biotech CFO Nougues sells $64k in shares